{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:39:31Z","timestamp":1787020771760,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T00:00:00Z","timestamp":1633996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018852","name":"hilfe f\u00fcr krebskranke kinder frankfurt e.v.","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100018852","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018821","name":"frankfurter stiftung f\u00fcr krebskranke kinder","doi-asserted-by":"crossref","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100018821","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>SAMHD1 mediates resistance to anti-cancer nucleoside analogues, including cytarabine, decitabine, and nelarabine that are commonly used for the treatment of leukaemia, through cleavage of their triphosphorylated forms. Hence, SAMHD1 inhibitors are promising candidates for the sensitisation of leukaemia cells to nucleoside analogue-based therapy. Here, we investigated the effects of the cytosine analogue CNDAC, which has been proposed to be a SAMHD1 inhibitor, in the context of SAMHD1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CNDAC was tested in 13 acute myeloid leukaemia (AML) cell lines, in 26 acute lymphoblastic leukaemia (ALL) cell lines, ten AML sublines adapted to various antileukaemic drugs, 24 single cell-derived clonal AML sublines, and primary leukaemic blasts from 24 AML patients. Moreover, 24 CNDAC-resistant sublines of the AML cell lines HL-60 and PL-21 were established. The\n                      <jats:italic>SAMHD1<\/jats:italic>\n                      gene was disrupted using CRISPR\/Cas9 and SAMHD1 depleted using RNAi, and the viral Vpx protein. Forced DCK expression was achieved by lentiviral transduction. SAMHD1 promoter methylation was determined by PCR after treatment of genomic DNA with the methylation-sensitive HpaII endonuclease. Nucleoside (analogue) triphosphate levels were determined by LC-MS\/MS. CNDAC interaction with SAMHD1 was analysed by an enzymatic assay and by crystallisation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Although the cytosine analogue CNDAC was anticipated to inhibit SAMHD1, SAMHD1 mediated intrinsic CNDAC resistance in leukaemia cells. Accordingly, SAMHD1 depletion increased CNDAC triphosphate (CNDAC-TP) levels and CNDAC toxicity. Enzymatic assays and crystallisation studies confirmed CNDAC-TP to be a SAMHD1 substrate. In 24 CNDAC-adapted acute myeloid leukaemia (AML) sublines, resistance was driven by DCK (catalyses initial nucleoside phosphorylation) loss. CNDAC-adapted sublines displayed cross-resistance only to other DCK substrates (e.g. cytarabine, decitabine). Cell lines adapted to drugs not affected by DCK or SAMHD1 remained CNDAC sensitive. In cytarabine-adapted AML cells, increased SAMHD1 and reduced DCK levels contributed to cytarabine and CNDAC resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Intrinsic and acquired resistance to CNDAC and related nucleoside analogues are driven by different mechanisms. The lack of cross-resistance between SAMHD1\/ DCK substrates and non-substrates provides scope for next-line therapies after treatment failure.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-021-02093-4","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T08:10:11Z","timestamp":1634026211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells"],"prefix":"10.1186","volume":"40","author":[{"given":"Tamara","family":"Rothenburger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Wratil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Pflantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsten","family":"Knecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Digianantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Temple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanze","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna-Mari","family":"Baldauf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie-May","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Rothweiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna","family":"Bilen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Farmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Bojkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Ferreir\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Geisslinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver T.","family":"Keppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark N.","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Jindrich","family":"Cinatl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,12]]},"reference":[{"issue":"11","key":"2093_CR1","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1158\/1535-7163.MCT-17-0110","volume":"16","author":"M Al Abo","year":"2017","unstructured":"Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, et al. TDP1 is critical for the repair of DNA breaks induced by Sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors. Mol Cancer Ther. 2017;16(11):2543\u201351. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0110.","journal-title":"Mol Cancer Ther"},{"issue":"4","key":"2093_CR2","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1124\/mol.59.4.725","volume":"59","author":"A Azuma","year":"2001","unstructured":"Azuma A, Huang P, Matsuda A, Plunkett W. 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest. Mol Pharmacol. 2001;59(4):725\u201331. https:\/\/doi.org\/10.1124\/mol.59.4.725.","journal-title":"Mol Pharmacol"},{"issue":"11","key":"2093_CR3","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1038\/nm.2964","volume":"18","author":"HM Baldauf","year":"2012","unstructured":"Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012;18(11):1682\u20137. https:\/\/doi.org\/10.1038\/nm.2964.","journal-title":"Nat Med"},{"issue":"9","key":"2093_CR4","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/ijms21093233","volume":"21","author":"K Bukowski","year":"2020","unstructured":"Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in Cancer chemotherapy. Int J Mol Sci. 2020;21(9):3233. https:\/\/doi.org\/10.3390\/ijms21093233.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2093_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/0923-2516(96)81081-8","volume":"146","author":"J Cinatl Jr","year":"1995","unstructured":"Cinatl J Jr, Cinatl J, Weber B, Rabenau H, G\u00fcmbel HO, Kornhuber B, et al. Replication of human herpesvirus type 6 (strain AJ) in JJHan cells grown in protein-free medium. Res Virol. 1995;146(2):125\u20139. https:\/\/doi.org\/10.1016\/0923-2516(96)81081-8.","journal-title":"Res Virol"},{"issue":"16","key":"2093_CR6","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1080\/14656566.2018.1524875","volume":"19","author":"M Czemerska","year":"2018","unstructured":"Czemerska M, Robak T, Wierzbowska A. The efficacy of sapacitabine in treating patients with acute myeloid leukemia. Expert Opin Pharmacother. 2018;19(16):1835\u20139. https:\/\/doi.org\/10.1080\/14656566.2018.1524875.","journal-title":"Expert Opin Pharmacother"},{"issue":"13","key":"2093_CR7","doi-asserted-by":"publisher","first-page":"9284","DOI":"10.1074\/jbc.M112.447201","volume":"288","author":"S de Silva","year":"2013","unstructured":"de Silva S, Hoy H, Hake TS, Wong HK, Porcu P, Wu L. Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells. J Biol Chem. 2013;288(13):9284\u201392. https:\/\/doi.org\/10.1074\/jbc.M112.447201.","journal-title":"J Biol Chem"},{"issue":"Pt 4","key":"2093_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486\u2013501. https:\/\/doi.org\/10.1107\/S0907444910007493.","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"key":"2093_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.20517\/cdr.2018.19","volume":"1","author":"TR Fenton","year":"2018","unstructured":"Fenton TR, Garrett MD, Wass MN, Michaelis M. What really matters - response and resistance in cancer therapy. Cancer Drug Resist. 2018;1:200\u20133. https:\/\/doi.org\/10.20517\/cdr.2018.19.","journal-title":"Cancer Drug Resist"},{"issue":"35","key":"2093_CR10","doi-asserted-by":"publisher","first-page":"14272","DOI":"10.1073\/pnas.1312033110","volume":"110","author":"E Franzolin","year":"2013","unstructured":"Franzolin E, Pontarin G, Rampazzo C, Miazzi C, Ferraro P, Palumbo E, et al. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc Natl Acad Sci U S A. 2013;110(35):14272\u20137. https:\/\/doi.org\/10.1073\/pnas.1312033110.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7377","key":"2093_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/nature10623","volume":"480","author":"DC Goldstone","year":"2011","unstructured":"Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011;480(7377):379\u201382. https:\/\/doi.org\/10.1038\/nature10623.","journal-title":"Nature"},{"key":"2093_CR12","doi-asserted-by":"publisher","unstructured":"Hanaoka K, Suzuki M, Kobayashi T, Tanzawa F, Tanaka K, Shibayama T, et al. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682). Int J Cancer. 1999;82(2):226\u201336.\u00a0https:\/\/doi.org\/10.1002\/(sici)1097-0215(19990719)82:2<226::aid-ijc13>3.0.co;2-x.","DOI":"10.1002\/(sici)1097-0215(19990719)82:2<226::aid-ijc13>3.0.co;2-x"},{"issue":"11","key":"2093_CR13","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1080\/15384101.2017.1314407","volume":"16","author":"N Herold","year":"2017","unstructured":"Herold N, Rudd SG, Sanjiv K, Kutzner J, Bladh J, Paulin CBJ, et al. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle. 2017;16(11):1029\u201338. https:\/\/doi.org\/10.1080\/15384101.2017.1314407.","journal-title":"Cell Cycle"},{"issue":"1","key":"2093_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169052","volume":"12","author":"JA Hollenbaugh","year":"2017","unstructured":"Hollenbaugh JA, Shelton J, Tao S, Amiralaei S, Liu P, Lu X, et al. Substrates and inhibitors of SAMHD1. PLoS One. 2017;12(1):e0169052. https:\/\/doi.org\/10.1371\/journal.pone.0169052.","journal-title":"PLoS One"},{"issue":"8","key":"2093_CR15","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1182\/blood-2011-02-337840","volume":"118","author":"I Homminga","year":"2011","unstructured":"Homminga I, Zwaan CM, Manz CY, Parker C, Bantia S, Smits WK, et al. In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia. Blood. 2011;118(8):2184\u201390. https:\/\/doi.org\/10.1182\/blood-2011-02-337840.","journal-title":"Blood"},{"issue":"11","key":"2093_CR16","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/nsmb.2692","volume":"20","author":"X Ji","year":"2013","unstructured":"Ji X, Wu Y, Yan J, Mehrens J, Yang H, DeLucia M, et al. Mechanism of allosteric activation of SAMHD1 by dGTP. Nat Struct Mol Biol. 2013;20(11):1304\u20139. https:\/\/doi.org\/10.1038\/nsmb.2692.","journal-title":"Nat Struct Mol Biol"},{"issue":"41","key":"2093_CR17","doi-asserted-by":"publisher","first-page":"E4305","DOI":"10.1073\/pnas.1412289111","volume":"111","author":"X Ji","year":"2014","unstructured":"Ji X, Tang C, Zhao Q, Wang W, Xiong Y. Structural basis of cellular dNTP regulation by SAMHD1. Proc Natl Acad Sci U S A. 2014;111(41):E4305\u201314. https:\/\/doi.org\/10.1073\/pnas.1412289111.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2093_CR18","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.2009.25.0209","volume":"28","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Westwood R, et al. Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. J Clin Oncol. 2010;28(2):285\u201391. https:\/\/doi.org\/10.1200\/JCO.2009.25.0209.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2093_CR19","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/S1470-2045(12)70436-9","volume":"13","author":"H Kantarjian","year":"2012","unstructured":"Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, et al. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012;13(11):1096\u2013104. https:\/\/doi.org\/10.1016\/S1470-2045(12)70436-9.","journal-title":"Lancet Oncol"},{"issue":"10","key":"2093_CR20","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/cncr.31923","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, Jabbour EJ, Garcia-Manero G, Kadia TM, DiNardo CD, Daver NG, et al. Phase 1\/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia. Cancer. 2019;125(10):1665\u201373. https:\/\/doi.org\/10.1002\/cncr.31923.","journal-title":"Cancer"},{"issue":"43","key":"2093_CR21","doi-asserted-by":"publisher","first-page":"E10022","DOI":"10.1073\/pnas.1805593115","volume":"115","author":"KM Knecht","year":"2018","unstructured":"Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L, et al. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc Natl Acad Sci U S A. 2018;115(43):E10022\u201331. https:\/\/doi.org\/10.1073\/pnas.1805593115.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"2093_CR22","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/15384101.2018.1480218","volume":"17","author":"KM Kodigepalli","year":"2018","unstructured":"Kodigepalli KM, Bonifati S, Tirumuru N, Wu L. SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis. Cell Cycle. 2018;17(9):1124\u201337. https:\/\/doi.org\/10.1080\/15384101.2018.1480218.","journal-title":"Cell Cycle"},{"issue":"1","key":"2093_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-015-0446-6","volume":"14","author":"R Kohnken","year":"2015","unstructured":"Kohnken R, Kodigepalli KM, Wu L. Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications. Mol Cancer. 2015;14(1):176. https:\/\/doi.org\/10.1186\/s12943-015-0446-6.","journal-title":"Mol Cancer"},{"issue":"15","key":"2093_CR24","doi-asserted-by":"publisher","first-page":"6874","DOI":"10.1158\/0008-5472.CAN-05-0288","volume":"65","author":"X Liu","year":"2005","unstructured":"Liu X, Guo Y, Li Y, Jiang Y, Chubb S, Azuma A, et al. Molecular basis for G2 arrest induced by 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation. Cancer Res. 2005;65(15):6874\u201381. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0288.","journal-title":"Cancer Res"},{"issue":"1","key":"2093_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1158\/1535-7163.MCT-07-0416","volume":"7","author":"X Liu","year":"2008","unstructured":"Liu X, Matsuda A, Plunkett W. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabino-pentofuranosylcytosine. Mol Cancer Ther. 2008;7(1):133\u201342. https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0416.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2093_CR26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00280-017-3483-6","volume":"81","author":"X Liu","year":"2018","unstructured":"Liu X, Jiang Y, Nowak B, Qiang B, Cheng N, Chen Y, et al. Targeting BRCA1\/2 deficient ovarian cancer with CNDAC-based drug combinations. Cancer Chemother Pharmacol. 2018;81(2):255\u201367. https:\/\/doi.org\/10.1007\/s00280-017-3483-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"2093_CR27","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1158\/1535-7163.MCT-18-1380","volume":"18","author":"X Liu","year":"2019","unstructured":"Liu X, Jiang Y, Takata KI, Nowak B, Liu C, Wood RD, et al. CNDAC-induced DNA double-Strand breaks cause aberrant mitosis prior to cell death. Mol Cancer Ther. 2019;18(12):2283\u201395. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1380.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"2093_CR28","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1080\/1042819031000099698","volume":"44","author":"K Lotfi","year":"2003","unstructured":"Lotfi K, Juliusson G, Albertioni F. Pharmacological basis for cladribine resistance. Leuk Lymphoma. 2003;44(10):1705\u201312. https:\/\/doi.org\/10.1080\/1042819031000099698.","journal-title":"Leuk Lymphoma"},{"issue":"Pt 4","key":"2093_CR29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658\u201374. https:\/\/doi.org\/10.1107\/S0021889807021206.","journal-title":"J Appl Crystallogr"},{"issue":"12","key":"2093_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.129","volume":"2","author":"M Michaelis","year":"2011","unstructured":"Michaelis M, Rothweiler F, Barth S, Cinatl J, van Rikxoort M, L\u00f6schmann N, et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2011;2(12):e243. https:\/\/doi.org\/10.1038\/cddis.2011.129.","journal-title":"Cell Death Dis"},{"key":"2093_CR31","doi-asserted-by":"publisher","unstructured":"Michaelis M, Wass MN, Cinatl J Jr. Drug-adapted cancer cell lines as preclinical models of acquired resistance. Cancer Drug Resist 2019;2:447\u2013456. https:\/\/doi.org\/10.20517\/cdr.2019.005.","DOI":"10.20517\/cdr.2019.005"},{"issue":"1\u20132","key":"2093_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","volume":"65","author":"T Mosmann","year":"1983","unstructured":"Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65(1\u20132):55\u201363. https:\/\/doi.org\/10.1016\/0022-1759(83)90303-4.","journal-title":"J Immunol Methods"},{"issue":"Pt 3","key":"2093_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1107\/S0907444996012255","volume":"53","author":"GN Murshudov","year":"1997","unstructured":"Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997;53(Pt 3):240\u201355. https:\/\/doi.org\/10.1107\/S0907444996012255.","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"issue":"1","key":"2093_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/s0304-3835(97)00402-3","volume":"123","author":"T Obata","year":"1998","unstructured":"Obata T, Endo Y, Tanaka M, Matsuda A, Sasaki T. Development and biochemical characterization of a 2\u2032-C-cyano-2\u2032-deoxy-1-beta-D-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080. Cancer Lett. 1998;123(1):53\u201361. https:\/\/doi.org\/10.1016\/s0304-3835(97)00402-3.","journal-title":"Cancer Lett"},{"issue":"7","key":"2093_CR35","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/j.1349-7006.2001.tb01163.x","volume":"92","author":"T Obata","year":"2001","unstructured":"Obata T, Endo Y, Tanaka M, Uchida H, Matsuda A, Sasaki T. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn J Cancer Res. 2001;92(7):793\u20138. https:\/\/doi.org\/10.1111\/j.1349-7006.2001.tb01163.x.","journal-title":"Jpn J Cancer Res"},{"issue":"1","key":"2093_CR36","doi-asserted-by":"publisher","first-page":"3475","DOI":"10.1038\/s41467-019-11413-4","volume":"10","author":"T Oellerich","year":"2019","unstructured":"Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nat Commun. 2019;10(1):3475. https:\/\/doi.org\/10.1038\/s41467-019-11413-4.","journal-title":"Nat Commun"},{"key":"2093_CR37","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.3762\/bjnano.10.166","volume":"10","author":"H Onafuye","year":"2019","unstructured":"Onafuye H, Pieper S, Mulac D, Cinatl J Jr, Wass MN, Langer K, et al. Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells. Beilstein J Nanotechnol. 2019;10:1707\u201315. https:\/\/doi.org\/10.3762\/bjnano.10.166.","journal-title":"Beilstein J Nanotechnol"},{"issue":"51","key":"2093_CR38","doi-asserted-by":"publisher","first-page":"43596","DOI":"10.1074\/jbc.C111.317628","volume":"286","author":"RD Powell","year":"2011","unstructured":"Powell RD, Holland PJ, Hollis T, Perrino FW. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem. 2011;286(51):43596\u2013600. https:\/\/doi.org\/10.1074\/jbc.C111.317628.","journal-title":"J Biol Chem"},{"issue":"1","key":"2093_CR39","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s42003-020-1052-8","volume":"3","author":"T Rothenburger","year":"2020","unstructured":"Rothenburger T, McLaughlin KM, Herold T, Schneider C, Oellerich T, Rothweiler F, et al. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine. Commun Biol. 2020;3(1):324. https:\/\/doi.org\/10.1038\/s42003-020-1052-8.","journal-title":"Commun Biol"},{"issue":"7","key":"2093_CR40","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/cancers11070923","volume":"11","author":"E Santoni-Rugiu","year":"2019","unstructured":"Santoni-Rugiu E, Melchior LC, Urbanska EM, Jakobsen JN, Stricker K, Grauslund M, et al. Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung Cancer: differences and similarities with acquired resistance. Cancers (Basel). 2019;11(7):923. https:\/\/doi.org\/10.3390\/cancers11070923.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2093_CR41","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/nm.4255","volume":"23","author":"C Schneider","year":"2017","unstructured":"Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23(2):250\u20135. https:\/\/doi.org\/10.1038\/nm.4255.","journal-title":"Nat Med"},{"issue":"6","key":"2093_CR42","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/1087057115575150","volume":"20","author":"KJ Seamon","year":"2015","unstructured":"Seamon KJ, Stivers JT. A high-throughput enzyme-coupled assay for SAMHD1 dNTPase. J Biomol Screen. 2015;20(6):801\u20139. https:\/\/doi.org\/10.1177\/1087057115575150.","journal-title":"J Biomol Screen"},{"issue":"13","key":"2093_CR43","doi-asserted-by":"publisher","first-page":"3693","DOI":"10.1007\/s00216-015-8588-3","volume":"407","author":"D Thomas","year":"2015","unstructured":"Thomas D, Herold N, Keppler OT, Geisslinger G, Ferreir\u00f3s N. Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2015;407(13):3693\u2013704. https:\/\/doi.org\/10.1007\/s00216-015-8588-3.","journal-title":"Anal Bioanal Chem"},{"issue":"7804","key":"2093_CR44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41586-020-2209-9","volume":"580","author":"M Touat","year":"2020","unstructured":"Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, et al. Mechanisms and therapeutic implications of hypermutation in gliomas. Nature. 2020;580(7804):517\u201323.","journal-title":"Nature"},{"issue":"Pt 12","key":"2093_CR45","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1107\/s0907444900013780","volume":"56","author":"A Vagin","year":"2000","unstructured":"Vagin A, Teplyakov A. An approach to multi-copy search in molecular replacement. Acta Crystallogr D Biol Crystallogr. 2000;56(Pt 12):1622\u20134. https:\/\/doi.org\/10.1107\/s0907444900013780.","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"Pt 4","key":"2093_CR46","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1107\/S0907444910045749","volume":"67","author":"MD Winn","year":"2011","unstructured":"Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67(Pt 4):235\u201342. https:\/\/doi.org\/10.1107\/S0907444910045749.","journal-title":"Acta Crystallogr D Biol Crystallogr."},{"issue":"1","key":"2093_CR47","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12977-015-0229-6","volume":"12","author":"S Wittmann","year":"2015","unstructured":"Wittmann S, Behrendt R, Eissmann K, Volkmann B, Thomas D, Ebert T, et al. Phosphorylation of murine SAMHD1 regulates its antiretroviral activity. Retrovirology. 2015;12(1):103. https:\/\/doi.org\/10.1186\/s12977-015-0229-6.","journal-title":"Retrovirology."},{"key":"2093_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000513696","volume":"24","author":"B Wu","year":"2021","unstructured":"Wu B, Mao ZJ, Wang Z, Wu P, Huang H, Zhao W, et al. Deoxycytidine kinase (DCK) mutations in human acute myeloid leukemia resistant to Cytarabine. Acta Haematol. 2021a;24:1\u20138. https:\/\/doi.org\/10.1159\/000513696.","journal-title":"Acta Haematol"},{"issue":"1","key":"2093_CR49","doi-asserted-by":"publisher","first-page":"189","DOI":"10.21037\/jtd-20-1889","volume":"13","author":"Y Wu","year":"2021","unstructured":"Wu Y, Niu Y, Wu Y, Chen X, Shen X, Gao W. SAMHD1 can suppress lung adenocarcinoma progression through the negative regulation of STING. J Thorac Dis. 2021b;13(1):189\u2013201. https:\/\/doi.org\/10.21037\/jtd-20-1889.","journal-title":"J Thorac Dis"},{"issue":"3","key":"2093_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/bjh.17352","volume":"193","author":"I Xagoraris","year":"2021","unstructured":"Xagoraris I, Vassilakopoulos TP, Drakos E, Angelopoulou MK, Panitsas F, Herold N, et al. Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. Br J Haematol. 2021;193(3):488\u201396. https:\/\/doi.org\/10.1111\/bjh.17352.","journal-title":"Br J Haematol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-021-02093-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-021-02093-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T08:11:59Z","timestamp":1634026319000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-021-02093-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,12]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2093"],"URL":"https:\/\/doi.org\/10.1186\/s13046-021-02093-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.07.19.452885","asserted-by":"object"}]},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,12]]},"assertion":[{"value":"6 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of peripheral blood and bone marrow aspirates was approved by the Ethics Committee of Frankfurt University Hospital (approval no. SHN-03-2017). All patients gave informed consent to the collection of samples and to the scientific analysis of their data and of biomaterial obtained for diagnostic purposes according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"317"}}